Accelerating the Commercialization of Cancer Research Results
The Canadian Cancer Society (CCS) and the Creative Destruction Lab (CDL) have launched a new world-class accelerator program for entrepreneurs and researchers developing innovations to improve the cancer experience globally and throughout the cancer care continuum. This program will educate, coach, finance and inspire seed-stage oncology-focused companies by pairing them with mentors, industry leaders and subject matter experts. Over 9 months and 5 sessions, accepted startups will be supported to tighten their strategic objectives, raise capital and engage with partners in the field. CDL Cancer will operate through the CDL Health and CDL Neuro streams based in CDL-Toronto (University of Toronto) and CDL-Vancouver (University of British Columbia) and is now accepting applications for the CDL 2022/23 Program Year. CDL Cancer is a foundational component of CCS’s new Centre for Cancer Prevention and Support, a national hub of research and innovation for cancer prevention and support services.
Elizabeth Eisenhauer, the 2021 Canada Gairdner Wightman Award Winner
Members of the CCRA extend their congratulations to Dr. Elizabeth Eisenhauer, OC, MD, FRCPC, FRSC who was recently announced as the recipient of the Read More »
Members of the CCRA extend their congratulations to Dr. Elizabeth Eisenhauer, OC, MD, FRCPC, FRSC who was recently announced as the recipient of the Read More »
Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and c... Read More »
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and c... Read More »